ClinicalTrials.gg
Not yet recruitingNCT07638501Updated Jun 10, 2026

Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer

A Phase 2 interventional study of Sintilimab + GC and SBRT 7Gy✖️5 QD in Biliary Tract Cancer (BTC), sponsored by Eastern Hepatobiliary Surgery Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Eastern Hepatobiliary Surgery Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Biliary Tract Neoplasms with a site in China — 94 open to participants now, 112 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
46th of 158
123 · median 61
Started
2026
with 33 others
Phase 2
95 of 177
53 open now
Primary completion
2028-06
later than 82 of 111 live
Registered
156th of 177
by date

Among the 177 studies in Biliary Tract Neoplasms with a site in China, this one is the 46th largest by planned enrollment of the 158 interventional ones that give a count, is one of 34 that started in 2026, is one of 95 in phase 2, reaches primary completion later than 82 of the 111 other live ones, and was the 156th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

94 of the 177 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

According to current clinical guidelines, first-line treatment for advanced biliary tract cancer (BTC) is the gemcitabine plus cisplatin (GC) regimen combined with immunotherapy, which has been shown to improve patient outcomes. Additionally, the combination of radiotherapy and immunotherapy may synergistically enhance antitumor efficacy. Therefore, this study aims to assess the efficacy and safety of first-line treatment with radiotherapy in combination with sintilimab and gemcitabine/cisplatin versus sintilimab in combination with gemcitabine/cisplatin in patients with previously untreated, unresectable locally advanced or metastatic BTC.

03

Conditions studied

  • Biliary Tract Cancer (BTC)

Keywords

  • First-line Therapy
  • Stereotactic Body Radiotherapy (SBRT)
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients voluntarily provide written , with authorization obtained from the patient or legal representative prior to any protocol-related procedures.
  2. Age ≥ 18 years and ≤ 75 years; both female and male
  3. or cytologically confirmed, unresectable advanced or adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma.
  4. No prior systemic anti-tumor treatment for BTC. Patients who developed recurrent disease >6 months after surgery with curative intent and, if given, >6 months after the completion of neo/ therapy (chemotherapy and/or radiation) will be eligible.
  5. At least 1 lesion that qualifies as a 1.1 Target Lesion (TL) at baseline.
  6. performance status of 0 or 1.
  7. ≥12 weeks.
  8. Adequate organ and bone marrow function within 14 days prior to initiation of study treatment, defined as follows:

    a.Hematology (without transfusion, granulocyte colony-stimulating factor [G-CSF], or other correction treatment within 14 days prior to screening): i. [HB] ≥ 90 g/L; ii. [ANC] ≥ 1.5 × 109/L; iii. count (PLT) ≥ 75 × 109/L b.Biochemistry Examination (without albumin infusion within 14 days prior to screening): i.Total (TBIL) ≤ 2 × (ULN) (for patients with Gilbert's syndrome, ≤ 3 × ULN) ii. (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN; iii.serum creatinine (Cr) ≤ 1.5 × ULN or clearance of creatinine (CCr) ≥ 50 mL/min ( formula);

    • Male: Creatinine clearance rate = [(140 - age) × weight] / (72 × serum Cr)
    • Female: Creatinine clearance rate= [(140 - age) × weight] / (72 × serum Cr) × 0.85 (Weight unit: kg; serum Cr unit: mg/dL)
  9. Patients with evidence of virus (HBV) infection, defined as detectable HBV DNA (≥10 IU/mL or above the lower limit of detection according to local laboratory standards) and positive HBsAg and/or anti-HBc, must receive antiviral therapy prior to study drug administration in accordance with institutional practice to ensure adequate viral suppression. Antiviral therapy must be continued throughout the study period and for at least 6 months after the last dose of study treatment. Patients who are anti-HBc positive but HBV DNA negative (\<10 IU/mL or below the lower limit of detection according to local laboratory standards) are not required to receive antiviral therapy unless HBV DNA rises to ≥10 IU/mL or exceeds the local lower limit of detection during study treatment.
  10. Female patients of childbearing age must have a documented negative urine or serum pregnancy test within 7 days prior to the first dose. If the urine test result is inconclusive, a serum test must be performed, and the serum result will be considered definitive. Female patients of childbearing age who have sexual intercourse with non-sterilized male partners must agree to take effective measures throughout the treatment and 120 days after the last dose.
  11. Male patients with female sexual partners of childbearing age must agree to take effective contraceptive measures throughout the treatment and 120 days after the last dose. The decision to discontinue contraception beyond this time frame should be discussed with the investigator.
  12. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study requirements.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed rare biliary tract tumors, including ampullary cancer, neuroendocrine tumors, sarcoma, or mucinous cystic neoplasms.
  2. Other active within the past 5 years or concurrent, except adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
  3. History of carcinomatous meningitis or .
  4. Known or allergic reaction to any study drug or any therein.
  5. Participation in another drug clinical trial within the past 3 months or concurrent enrollment in another clinical study, unless observational, non-interventional, or follow-up phase of an interventional study.
  6. Uncontrolled concurrent illness, including but not limited to moderate to severe ascites, uncontrolled or moderate-to-large pleural or pericardial effusion, uncontrolled acute or chronic pancreatitis, active hemorrhagic disorder, or severe chronic gastrointestinal disease associated with diarrhea.
  7. History of allogeneic organ or bone marrow transplantation.
  8. History of significant cardiovascular or cerebrovascular disease, including:

    1. congestive heart failure ( Class ≥II), unstable angina, myocardial infarction, uncontrolled arrhythmia, or cerebrovascular accident within 12 months prior to first dose;
    2. \<50%;
    3. interval (QTc) >480 ms (Fridericia formula);
    4. poorly controlled hypertension (systolic ≥150 mmHg or diastolic ≥100 mmHg based on ≥2 measurements);
    5. history of hypertensive crisis or hypertensive encephalopathy.
  9. Active disease within 2 years prior to first dose or history of autoimmune disease with potential for relapse, including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (except hypothyroidism controlled by hormone replacement therapy).
  10. Prior anti-cancer therapy-related adverse events not recovered to Grade ≤1 or baseline, with Grade ≤2 neuropathy possibly eligible per investigator assessment.
  11. Active infection, including tuberculosis or (HIV).
  12. Diagnosis of immunodeficiency, or chronic systemic therapy (daily dose >10 mg prednisone equivalent) or any other form of therapy within 7 days prior to first dose of study intervention.
  13. History of gastrointestinal bleeding within 6 months prior to study treatment, documented predisposition to gastrointestinal hemorrhage, or known hereditary or acquired bleeding (e.g., coagulopathy) or thrombotic tendency.
  14. Major surgery (excluding ) with incomplete recovery from surgery or surgical complications, or incomplete wound healing, prior to start of study intervention, or anticipated need for major surgery during the study period.
  15. Receipt of within 28 days prior to first dose of study intervention, or anticipated need for live attenuated vaccine during study treatment or within 60 days after last dose.
  16. Any other condition judged by the investigator to potentially interfere with study outcomes or lead to premature study termination, including alcohol or drug abuse, severe comorbidity requiring concomitant therapy (including psychiatric illness), severe laboratory abnormality, or family or social factors affecting patient safety or data collection.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    SBRT+sintilimab+GC

    SBRT: total dose of 35 Gy in 5 fractions (7 Gy per fraction); Followed by Sintilimab (200 mg, iv, d1, q3w) in combination with gemcitabine (1000 mg/m², iv, d1/d8, q3w), cisplatin (25 mg/m², iv, d1/d8, q3w)

    Drug: Sintilimab + GC · Radiation: SBRT 7Gy✖️5 QD

  • Active comparator
    sintilimab+GC

    Sintilimab (200 mg, iv, d1, q3w) combined with gemcitabine (1000 mg/m², iv, d1/d8, q3w) and cisplatin (25 mg/m², iv, d1/d8, q3w)

    Drug: Sintilimab + GC

Interventions

  • DrugSintilimab + GC

    Drug page: SintilimabStudies of SintilimabSintilimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants receive sintilimab (200 mg, intravenous \[IV\], day 1), gemcitabine (1000 mg/m², IV, day 1 and day 8), and cisplatin (25 mg/m², IV, day 1 and day 8) every 3 weeks (q3w). The drugs are administered sequentially with an interval of \>30 minutes between each, preferably on the same day. Different drugs require separate infusion bags and filters.

  • RadiationSBRT 7Gy✖️5 QD

    Stereotactic body radiotherapy (SBRT) is delivered only to participants in the experimental arm with total dose of 35 Gy in 5 fractions (7 Gy per fraction). SBRT is completed within 1 week before the first cycle of sintilimab+GC.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    The time from the date of randomization to the date of the first documented tumor progression as determined by the investigator (per RECIST 1.1), or death due to any cause.

    Time frame: Through out the study (up to 3 years)

Secondary outcomes

  1. Progression-free Survival (PFS)

    The time from the date of randomization to the date of the first documented tumor progression as determined by the investigator (per mRECIST), or death due to any cause.

    Time frame: Through out the study (up to 3 years)

  2. Objevtive Response Rate (ORR)

    Disease assessments based on investigator assessments were determined by using RECIST v1.1/mRECIST. The ORR was defined as the percentage of patients with complete response (CR) or partial response (PR).

    Time frame: Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.

  3. Disease Control Rate (DCR)

    Disease control rate based on investigator assessments according to RECIST v1.1/mRECIST was defined as the proportion of CR, PR or stable disease (SD).

    Time frame: Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.

  4. Time to Response (TTR)

    The time from randomization to the first evaluation of the tumor as CR, PR (per RECIST v1.1 and mRECIST).

    Time frame: Through out the study (up to 3 years)

  5. Duration of Response (DoR)

    The time from the first evaluation of the tumor as CR, PR to the first evaluation as PD (per RECIST v1.1 and mRECIST) or death from any cause.

    Time frame: Through out the study (up to 3 years)

  6. Overall Survival (OS)

    The time from the date of randomization until death due to any cause.

    Time frame: Through out the study (up to 3 years)

  7. Incidence of Adverse Events (AEs)

    The incidence and severity of adverse events (AEs), serious adverse events (SAEs), immune-related adverse events (irAEs), and laboratory abnormalities, assessed according to the NCI-CTCAE v5.0.

    Time frame: Through out the study (up to 3 years)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 10, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jun 15, 2028
CompletionEst.
Jun 15, 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07638501
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Responsible party
Shen Feng (Professor, Eastern Hepatobiliary Surgery Hospital) — Principal investigator
First posted
Jun 10, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jun 15, 2028 (estimated)
Completion
Jun 15, 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Feng Shen
Contact
shenfengehbh@sina.com
+86 13901651428
Feng Shen
principal investigator · Eastern Hepatobiliary Surgery Hospital
Ruiliang Ge
principal investigator · Eastern Hepatobiliary Surgery Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion